VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Iclusig (Ariad)
- INDICATIONS: Chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 24 hours
- FDA APPROVAL DATE: 12/14/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antacids, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Histamine H2 antagonists, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Proton pump inhibitors, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors or inducers, Telaprevir, Telithromycin, Voriconazole
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
